Biotron Completes phase two HIV-1 trial recruitment
- Biotron (BIT) completes recruitment of the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225
- The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatment
- Participants will receive 200 milligrams of BIT225 daily over 12 weeks to determine any changes in immune, inflammation, viral and immune activation markers
- The trial is scheduled to be completed in January 2023 with preliminary results expected in mid-2023
- The company is up 4.35 per cent on the market with shares trading at 4.8 cents at 2:15 pm AEDT
